finanzen.net
23.06.2018 16:12
Bewerten
(0)

Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

DRUCKEN

ORLANDO, Florida, June 23, 2018 /PRNewswire/ --

Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin

Findings from CONFIRM - a large real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) versus insulin glargine U300 - will be presented on Monday, 25 June 2018 at the American Diabetes Association's 78th Scientific Sessions (ADA) in Orlando, US. The retrospective, non-interventional comparative effectiveness study, which included more than 4,000 adults with type 2 diabetes who were starting basal insulin for the first time, showed that after six months those treated with Tresiba® had significantly lower HbA1c compared to those treated with insulin glargine U300 (-1.5% vs. -1.2% respectively; p=0.029).[1]

As a secondary endpoint, there was a 30% lower rate of hypoglycaemic episodes with Tresiba® compared to insulin glargine U300 (p=0.045).[1] In this study, hypoglycaemic events, ranging from mild to severe, were registered using the International Classification of Diseases (ICD) codes 9/10 following diagnosis from a physician.[2]

This real-world study also showed in another secondary endpoint that people treated with Tresiba® were more likely to stay on their treatment. Those treated with insulin glargine U300 had a 37% higher rate of discontinuing treatment after two years (p<0.001).[1]

"Real-world studies are important to understanding how clinical trials may translate into real value for patients in everyday clinical practice," said Todd Hobbs, vice president and US chief medical officer of Novo Nordisk. "The CONFIRM results add to the body of evidence on Tresiba® for adults with type 2 diabetes."

About the CONFIRM study   

The CONFIRM study is a retrospective, non-interventional comparative effectiveness study that investigated Tresiba® and insulin glargine U300 (Toujeo®) in 4,056 insulin-naïve (defined as no evidence of basal insulin use at least 365 days prior to index date) adults with type 2 diabetes in the US. Study groups were equal in size (n=2,028) and patients in each group were comparable after matching for baseline characteristics.

Patients were uncontrolled on one or more oral antidiabetic drugs or a GLP-1 (glucagon-like peptide-1) receptor agonist and prescribed Tresiba® or insulin glargine U300 according to local practice. Electronic health records were sourced from multiple health systems in the US. The primary endpoint was change in HbA1c (blood sugar control) from baseline to six months follow-up. Secondary endpoints included rate of hypoglycaemia, proportion of patients with at least one hypoglycaemic episode and the rate of treatment discontinuation.

As with all real-world studies, CONFIRM was not randomised and it carries the limitations of real-world evidence. This includes potential under-reporting of hypoglycaemia (however, this is the case in both treatment arms in CONFIRM meaning that the rate ratio as well as the odds ratio are expected to be preserved), and the short follow-up period of 3-6 months (though this corresponds to when the largest changes in HbA1c tend to occur and is commonly used in many trials). Additionally, in CONFIRM there is only evidence of prescribed basal insulin and not actual use (whether the medication was picked up at the pharmacy).

About hypoglycaemia   

Hypoglycaemia occurs when blood sugar levels are too low and cannot provide the body's organs with the energy they need. Hypoglycaemia can cause a range of symptoms including confusion, trembling, sweating, increased heart rate, difficulty with concentration and speech, and in severe cases can lead to a seizure or coma.[3]-[6]

About Tresiba®

Tresiba® (insulin degludec) is a once-daily basal insulin that provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect.[7],[8] It has been shown to provide a lower risk of overall, nocturnal and severe hypoglycaemia, and low variability in blood sugar levels versus insulin glargine U100.[8],[9] Tresiba® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally. It is now commercially available in more than 61 countries.

About Novo Nordisk   

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

References   

  • Tibaldi J, Haldrup S, Sandberg V, et al. Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM): A Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in 4,056 Insulin-Naïve Patients with Type 2 Diabetes (T2D) Oral/poster presentation. 78th Annual Scientific Sessions of the American Diabetes Asosciation (ADA), Orlando, Florida, US; 22-26 June 2018.
  • Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008; 8:4.
  • Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36:1384-1395.
  • International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at http://ihsgonline.com/understanding-hypoglycaemia/diagnosis. Last accessed: June 2018.
  • Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007; 117:868-870.
  • Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013; 9:155-163.
  • Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800.
  • EMA. Tresiba® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Last accessed: June 2018.
  • Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723-732.
  • Further information   

    Media:   

    Katrine Sperling, +45-4442-6718, krsp@novonordisk.com

    Åsa Josefsson, +45-3079-7708, aajf@novonordisk.com

    Michael Bachner (US), +1-609-664-7308, mzyb@novonordisk.com

    Investors:   

    Peter Hugreffe Ankersen, +45-3075-9085, phak@novonordisk.com

    Anders Mikkelsen, +45-3079-4461, armk@novonordisk.com

    Christina Kjær, +45-3079-3009, cnje@novonordisk.com

    Jetzt noch schnell anmelden!

    Wie managen Sie in unruhigen Marktphasen erfolgreich die Risiken in Ihrem Portfolio? Das erklären die Investment-Profis Martin Goersch und Sebastian Steyer heute ab 18 Uhr.
    Jetzt kostenlos anmelden!
    Anzeige
    Anzeige
    Börse Stuttgart Anlegerclub

    Fünf deutsche Internet-Aktien, die Sie kennen sollten!

    Das Gute liegt oft so nah. Heimische Internet-Unternehmen rollen den Markt auf. Im neuen Anlegermagazin erwartet Sie ein Special über deutsche Internet-Aktien, die Sie kennen sollten.
    Kostenfrei registrieren und lesen!

    Heute im Fokus

    DAX gibt ab -- Wall Street in Rot -- Deutsche Bank hält trotz jüngster Turbulenzen an Jahreszielen fest -- innogy kappt Jahresziele und Dividendenaussicht -- ASOS, Goldman Sachs im Fokus

    Trump kritisiert US-Notenbank erneut heftig. Apple-Staranalyst hat miese Prognosen für Apple 2019 im Gepäck. Italiens Regierung einigt sich auf neuen Haushaltsentwurf. Mercedes senkt wegen Atempause im Handelsstreit Preise in China. H&M gelingt Schlussspurt in Q4. Henkel-Chef will Konzern nicht aufspalten.

    Die 5 beliebtesten Top-Rankings

    Gut bezahlte Jobs
    Bei diesen Top-Konzernen brauchen Bewerber keinen Abschluss
    Diese Aktien hat Warren Buffett im Depot
    Einige Änderungen unter den Top-Positionen
    Ausgaben auf Rekordniveau
    Die beliebtesten Weihnachtsgeschenke 2018
    Das sind die reichsten Länder Welt 2018
    USA nicht mal in den Top 10
    In diesen Ländern ist Netflix am teuersten
    Hier müssen Abonnenten tief in die Tasche greifen
    mehr Top Rankings

    Umfrage

    Glauben Sie, dass es noch zu einem geordneten Brexit kommen wird?

    finanzen.net Brokerage

    Online Brokerage über finanzen.net

    Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
    Zur klassischen Ansicht wechseln
    Kontakt - Impressum - Werben - Pressemehr anzeigen
    Top News
    Beliebte Suchen
    DAX 30
    Öl
    Euro US-Dollar
    Bitcoin
    Goldpreis
    Meistgesucht
    Saint-Gobain S.A. (Compagnie de Saint-Gobain)872087
    Deutsche Bank AG514000
    Daimler AG710000
    Amazon906866
    Fresenius SE & Co. KGaA (St.)578560
    Apple Inc.865985
    CommerzbankCBK100
    BASFBASF11
    Steinhoff International N.V.A14XB9
    Wirecard AG747206
    Volkswagen (VW) AG Vz.766403
    Allianz840400
    Deutsche Telekom AG555750
    TeslaA1CX3T
    Aurora Cannabis IncA12GS7